MOLLY SCHILD

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; (4) Issues related to S. 1932 - Better Care, Lower Cost Act; (5) Issued related to CMS-4159-P -Proposed Rule - Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; (6) Issues related to H.R. 4302 - Protecting Access to Medicare Act, and Rate Notice; and (7) Issues related to S. 1871 - The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform;and (6) Senate Tax Extender bill (EXPIRE Act).

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform; and(6) Senate Tax Extender bill (EXPIRE Act); and (7) Issues related to H.R. 3367 - The Small Business and Family Relief Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; (3) Issues Related to Public Law 112-144 - FDA Safety and Innovations Act (medical device user fee); (4) Issues related to the Health Information Technology for Economic and Clinical Health (HITECH) Act; (5) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability,health information technology, transparency, employer regulations, and taxes and fees. (6) Issues related to S. 2546 - Auto Enroll Repeal Act; (7) Issues related to S. 1330 - Realistic Employer Responsibility Act; (8) Issues related to S. 701 - The Forty Hours is Full-Time Act; and (9) Issues related to S. 1729 - Expanded Consumer Choice Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues related to the Affordable Care Act's implementation, including Medical Loss Ration, taxes, Exchanges, Essential health Benefits, premium affordability, health information technology, transparency, and employer regulations; (4) Issues related to S. 1729 - Expanded Consumer Choice Act; and (5) Issues related toH.R. 2575 - Save American Workers Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; (3) Issues Related to Public Law 112-144 - FDA Safety and Innovations Act (medical device user fee); (4) Issues related to the Health Information Technology for Economic and Clinical Health (HITECH) Act; (5) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability,health information technology, transparency, employer regulations, and taxes and fees. (6) Issues related to S. 2546 - Auto Enroll Repeal Act; (7) Issues related to S. 1330 - Realistic Employer Responsibility Act; (8) Issues related to S. 701 - The Forty Hours is Full-Time Act; and (9) Issues related to S. 1729 - Expanded Consumer Choice Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; (4) Issues related to S. 1932 - Better Care, Lower Cost Act; (5) Issued related to CMS-4159-P -Proposed Rule - Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; (6) Issues related to H.R. 4302 - Protecting Access to Medicare Act, and Rate Notice; and (7) Issues related to S. 1871 - The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; (4) Issues related to S. 1932 - Better Care, Lower Cost Act; (5) Issued related to CMS-4159-P -Proposed Rule - Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; (6) Issues related to H.R. 4302 - Protecting Access to Medicare Act, and Rate Notice; and (7) Issues related to S. 1871 - The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues pertaining to entitlement reform, Medicare Advantage, Medicaid Dual Eligibles, and Medicare reimbursement and enrollment; (4) Issues related to S. 1932 - Better Care, Lower Cost Act; (5) Issued related to CMS-4159-P -Proposed Rule - Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; and (6) Issues related to H.R. 4302 - Protecting Access to Medicare Act, and Rate Notice.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; (3) Issues Related to Public Law 112-144 - FDA Safety and Innovations Act (medical device user fee); (4) Issues related to the Health Information Technology for Economic and Clinical Health (HITECH) Act; (5) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability,health information technology, transparency, employer regulations, and taxes and fees. (6) Issues related to S. 2546 - Auto Enroll Repeal Act; (7) Issues related to S. 1330 - Realistic Employer Responsibility Act; (8) Issues related to S. 701 - The Forty Hours is Full-Time Act; and (9) Issues related to S. 1729 - Expanded Consumer Choice Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform;and (6) Senate Tax Extender bill (EXPIRE Act).

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform; and(6) Senate Tax Extender bill (EXPIRE Act); and (7) Issues related to H.R. 3367 - The Small Business and Family Relief Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of 2010; (3) Issues Related to Public Law 112-144 - FDA Safety and Innovations Act (medical device user fee); (4) Issues related to the Health Information Technology for Economic and Clinical Health (HITECH) Act; (5) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability,health information technology, transparency, employer regulations, and taxes and fees. (6) Issues related to S. 2546 - Auto Enroll Repeal Act; (7) Issues related to S. 1330 - Realistic Employer Responsibility Act; (8) Issues related to S. 701 - The Forty Hours is Full-Time Act; and (9) Issues related to S. 1729 - Expanded Consumer Choice Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues related to the Affordable Care Act's implementation, including Medical Loss Ration, taxes, Exchanges, Essential health Benefits, premium affordability, health information technology, transparency, and employer regulations, (4) Issues related to H.R. 2995 - Unnecessary Cap Act of 2013; and (5) Issues related toS. 1729 - Expanded Consumer Choice Act.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform.

(1) Issues related to Pulic Law 111-148 - the Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); and (5) Corporate tax reform.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform.

(1) Issues related to Pulic Law 111-148 - the Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by the Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); and (5) Corporate tax reform.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act (provisions related to new taxes, fees, and employer requirements); (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 763 - To repeal the annual fee on health insurance providers enacted by The Patient Protection and Affordable Care Act; (4) Issues raised by S. 603 - Jobs and Premium Protection Act (repeals annual insurer fee); (5) Corporate tax reform.

(1) Public Law 111-148 The Patient Protection and Affordable Care Act; (2) Public Law 111-152 Health Care and Education Reconciliation Act of 2010; and (3) H.R. 1580 Medicare Beneficiary Preservation of Choice Act of 2011 (expands Medicare open enrollment and disenrollment opportunities). General Medicare/Medicaid reimbursement issues, such as the sustainable growth ration (SGR) and efforts to improve and expand care delivery models. including for dual eligibles.

(1) Issues related to Public Law 111-148 The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152 Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 2077 - MLR Repeal Act of 2011(repeal ACA's Medical Loss Ratio requirements); (4) Issues related to Public Law 112-144 FDA Safety and Innovation Act (medical device user fee); (5) Issues related to the Health Information Technology for Economic and Clinical Health (HITECH) Act; and (6) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees.

(1) Issues related to Public Law 111-148 - The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152 - Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 2077 - MLR Repeal Act of 2011 (repeal ACA's Medical Loss Ratio requirements); (4) Issues related to Public Law 112-144 - FDA Safety and Innovation Act (medical device user fee); (5) Issues related to the Health Information Technology for Economic and Clinical Health (HITECH) Act; and (6) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees.

(1) Issues related to Public Law 111-148 The Patient Protection and Affordable Care Act; (2) Issues related to Public Law 111-152 Health Care and Education Reconciliation Act of 2010; (3) Issues raised by H.R. 2077 - MLR Repeal Act of 2011(repeal ACA's Medical Loss Ratio requirements); and (4) Issues related to implementation of the Affordable Care Act, including Exchanges, Essential Health Benefits, affordability, health information technology, transparency, employer regulations, and taxes and fees.

(1) Issues related to Public Law 111-148 The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues raised by H.R. 5979 Medicaid Accountability and Care Act of 2012 (capping the federal government's share of every state's Medicaid expenditures); (4) Issues raised by H.R. 6498 Medicaid Integrity Act (require independent audits and actuarial services under Medicaid managed care programs); (5) Issues raised by H.R. 6482 The Preventative Health Savings Act of 2012 (wellness programs and population health); and (6) Issues pertaining to entitlement reform, Medicare Advantage, premium support models, reimbursement and enrollment.

(1) Issues related to Public Law 111-148- The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of2010 (provisions related to Medicaid and Medicare); (3) Issues raised by H.R. 5979 - Medicaid Accountability and Care Act of2012 (capping the federal government's share of every state's Medicaid expenditures); (4) Issues raised by H.R. 6498 - Medicaid Integrity Act (require independent audits and actuarial services under Medicaid managed care programs); (5) Issues raised by H.R. 6482- The Preventative Health Savings Act of20l2 (wellness programs and population health); (6) Issues pertaining to entitlement reform, Medicare Advantage, premium support models, reimbursement and enrollment; and (7) Issues related to the reauthorization of special needs plans (SNPs).

(1) Issues related to Public Law 111-148 The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues raised by H.R. 5979 Medicaid Accountability and Care Act of 2012 (capping the federal government's share of every state's Medicaid expenditures); (4) Issues raised by H.R. 6498 Medicaid Integrity Act (require independent audits and actuarial services under Medicaid managed care programs); (5) Issues raised by H.R. 6482 The Preventative Health Savings Act of 2012 (wellness programs and population health); and (6) Issues pertaining to entitlement reform, Medicare Advantage, premium support models, reimbursement and enrollment.

(1) Issues related to Public Law 111-148- The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of2010 (provisions related to Medicaid and Medicare); (3) Issues raised by H.R. 5979 - Medicaid Accountability and Care Act of2012 (capping the federal government's share of every state's Medicaid expenditures); (4) Issues raised by H.R. 6498 - Medicaid Integrity Act (require independent audits and actuarial services under Medicaid managed care programs); (5) Issues raised by H.R. 6482- The Preventative Health Savings Act of20l2 (wellness programs and population health); (6) Issues pertaining to entitlement reform, Medicare Advantage, premium support models, reimbursement and enrollment; and (7) Issues related to the reauthorization of special needs plans (SNPs).

(1) Issues related to Public Law 111-148- The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152- Health Care and Education Reconciliation Act of2010 (provisions related to Medicaid and Medicare); (3) Issues raised by H.R. 5979 - Medicaid Accountability and Care Act of2012 (capping the federal government's share of every state's Medicaid expenditures); (4) Issues raised by H.R. 6498 - Medicaid Integrity Act (require independent audits and actuarial services under Medicaid managed care programs); (5) Issues raised by H.R. 6482- The Preventative Health Savings Act of20l2 (wellness programs and population health); (6) Issues pertaining to entitlement reform, Medicare Advantage, premium support models, reimbursement and enrollment; and (7) Issues related to the reauthorization of special needs plans (SNPs).

(1) Issues related to Public Law 111-148 The Patient Protection and Affordable Care Act (provisions related to Medicaid and Medicare); (2) Issues related to Public Law 111-152 Health Care and Education Reconciliation Act of 2010 (provisions related to Medicaid and Medicare); (3) Issues raised by H.R. 5979 Medicaid Accountability and Care Act of 2012 (capping the federal government's share of every state's Medicaid expenditures); (4) Issues raised by H.R. 6498 Medicaid Integrity Act (require independent audits and actuarial services under Medicaid managed care programs); (5) Issues raised by H.R. 6482 The Preventative Health Savings Act of 2012 (wellness programs and population health); and (6) Issues pertaining to entitlement reform, Medicare Advantage, premium support models, reimbursement and enrollment.

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid).

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); s. 848 (Diasclosure of Medicare Provider data); HR 1031.

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); s. 848 (Diasclosure of Medicare Provider data); HR 1031.

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid)

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number);

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number);

S. 31 and S. 44 (Allow HHS to directly negotiate drug prices); S. 560 and HR 999 (Establishes Medicare-run Part D PDP nationwide); Proposals to extend the "Doc Fix" beyond 12/31/ 2011. Medicaid Maintenance of Effort repeal (No Bill Number); Medicare Advantage Open Enrollment period (No Bill Number); S. 848 (Disclosure of Medicare provider data); HR 1031 (Medicaid).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); HR 2077 S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR a839 (Antitrust exemption for commurnity pharmacists); S. 1058/HR 1971 (forced disclosure of PBM proprietary pricing and other competitive information). HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA Annual insurer fee).

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out ACA provisions per state-passed legislation); HR 2077 (MLR repeal) S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill). HR 1839 (Antitrust exemption for community pharmacists); S. 1058/HR 1971 (Forced disclosure of PBM proprietary pricing and other competitive information); HR 371 (Health Choice Act); HR 2011 (Repeal MLR); HR 1370 (Repeal ACA annual fee in insurers)

HR 2 (repeal ACA); HR 2 (De-fund ACA); HR 1010 (directs SCOTUS to expedite appeal on Constitutionality of ACA); H. Res. 9 (Instructs Committees to develop proposals as alternatives to ACA); HR 4 (repeal 1099 provision of ACA); HR 21/S. 19 (repeal ACA's individual mandate); H. J. Res 19 (Expression of disapproval of HHS Regulation on MLR); HR 1206 (Exclude broker remuneration from MLR); S. 244 ( allows states to opt out of enumerated ACA provisions per state-passed legislation); S. 248 (accelerates from 2017 to 2014 the right of states to seek federal waiver from specified provisions of ACA); S. 312/HR 605 (repeals ACA provision barring use of FSA/HSA money for OTC medications); HR 1150 (amends McCarran-Ferguson); HR 979 (imposes new requirements on PBMs and insurers who participate in FEHBP); S. 27 (prohibits settlement of patent infringement cases which results in delay of generics coming to market); S. 493 (Small Business bill).